drugset / Trial / NCT03992755
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
Timeline
- Start
- 2019-07-18
- Primary completion
- 2025-05-31
- Completion
- 2025-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Treprostinil | Other / unclassified | 25 ug | Inhaled |
| Subject | Treprostinil | Other / unclassified | 50 ug | Inhaled |
| Subject | Treprostinil | Other / unclassified | 75 ug | Inhaled |
| Subject | Treprostinil | Other / unclassified | 100 ug | Inhaled |
| Subject | Treprostinil | Other / unclassified | 200 ug | Inhaled |